View details of this raise on Seedstage

The Woodlands, TX

Developing a mobile device to prevent nerve damage from chemotherapy.

• Innovative Device: Eisana Health has developed the only mobile device that allows functionality in hands and feet while cooling.
• Functional Prototype: The company has completed a functional prototype and a usability study in humans.
• Patent Filings: Several patents have been filed in the US and selected countries.
• Significant Market Need: Approximately 500,000 US cancer patients per year could benefit from this device.
• Experienced Team: The founder and team have decades of relevant experience in oncology product development.

Eisana Health is developing a mobile device designed to prevent chemotherapy-induced peripheral neuropathy (CIPN), a common and debilitating side effect of chemotherapy that affects nerve endings in the hands and feet. The company has created a functional prototype that allows patients to maintain mobility and functionality while cooling, addressing a significant gap in current treatment options. The device is intended to be used during chemotherapy sessions and at home, providing continuous cooling to prevent nerve damage. Eisana Health has filed several patents and received a $400k SBIR Contract from the National Cancer Institute to further develop this innovative solution.

The company aims to bring this device to market to help the estimated 500,000 U.S. cancer patients annually who are at risk of CIPN. With a team experienced in oncology product development, Eisana Health is focused on finalizing the design for mass production and conducting clinical validation. The funds raised will be allocated towards engineering development, manufacturing, clinical validation, and patent protection. Eisana Health’s mission is to improve the quality of life for cancer patients by reducing the long-term side effects of chemotherapy, allowing them to maintain independence and functionality during and after treatment.

Company Info

Eisana Health develops a mobile cooling device to prevent nerve damage from chemotherapy, enhancing patient quality of life.

Eisana Health is focused on reducing the permanent nerve damage caused by chemotherapy, known as chemotherapy-induced peripheral neuropathy (CIPN). The company has developed a mobile device that allows patients to maintain functionality in their hands and feet while cooling, which is essential for preventing this debilitating side effect. Their innovative solution includes gloves and booties that provide continuous cooling, allowing patients to remain mobile and independent during treatment.

The device is designed to be used both in clinical settings and at home, addressing the needs of approximately 500,000 US cancer patients annually who are at risk of CIPN. Eisana Health’s approach integrates a chiller system with wearable cooling gear, ensuring that patients can continue their daily activities without interruption. The company has completed a functional prototype and usability study, and has filed several patents to protect its technology.